DNA Manufacturing Market Size & Growth Forecast 2027–2036, By Segments (End-use, Grade, Type, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
DNA Manufacturing Market size stood at USD 7.37 billion in 2026 and is predicted to grow at a 18.51% CAGR from 2027 to 2036, reaching USD 40.27 billion by 2036. The industry revenue for 2027 is calculated at USD 8.55 billion.
Get more details on this report
Request Free Sample ReportDNA Manufacturing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 49% market share in 2026, supported by advanced biotechnology infrastructure, strong R&D capabilities, and demand for synthetic DNA in drug discovery, precision medicine, diagnostics, and therapeutic development.
- Asia Pacific is the fastest-growing region, driven by expanding biotechnology industries, life sciences investments, and rising demand for genetic materials in genomics, molecular diagnostics, vaccine development, and advanced therapeutic research.
Segment Momentum
- Pharmaceutical and biotechnology companies accounted for 51.6% of the market in 2026, driven by demand for manufactured DNA in drug discovery, diagnostics, vaccine development, genetic research, and advanced therapeutic development.
- GMP-grade DNA is the largest and fastest-growing grade segment, supported by stringent requirements for quality, consistency, and traceability in clinical and therapeutic applications, particularly as cell and gene therapy programs expand.
Market Expansion Drivers
- DNA synthesis demand in research.
- Gene therapy and synthetic biology.
- Large-scale DNA manufacturing.
Leading Market Participants
- Key players in the DNA manufacturing market include Thermo Fisher Scientific (USA), Twist Bioscience (USA), GenScript (China), Eurofins Scientific (Luxembourg), Integrated DNA Technologies (USA), BGI Genomics (China), ATUM (USA), Evonetix (UK), Synbio Technologies (China), Codex DNA (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 7.37 billion
- 2027 Estimated Market Size: USD 8.55 billion
- Projected Market Size: USD 40.27 billion by 2036
- Growth Forecast: 18.51% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: End-use (Pharmaceutical and Biotechnology Companies) | Grade (GMP Grade) | Type (Synthetic DNA) | Application (Cell & Gene Therapy)
- Emerging Opportunity Segment: End-use (Pharmaceutical and Biotechnology Companies) | Grade (GMP Grade) | Type (Synthetic DNA) | Application (Cell & Gene Therapy)
Market Growth Drivers and Industry Trends
DNA synthesis demand in research
The growing demand for DNA synthesis in research is driving the DNA manufacturing market as laboratories increasingly require customized genetic sequences for molecular biology, genomics, diagnostics, and biotechnology applications. Synthetic DNA enables researchers to construct genes, modify biological pathways, and investigate genetic functions with greater flexibility. Expanding research activity in life sciences and increasing reliance on engineered genetic material are supporting continued demand for high-quality DNA manufacturing capabilities.
Gene therapy and synthetic biology
The expansion of gene therapy and synthetic biology is significantly supporting DNA manufacturing demand by increasing the need for precisely designed and scalable genetic materials. Gene therapy development requires customized DNA constructs for research, vector development, and therapeutic production, while synthetic biology relies on engineered sequences to create and modify biological systems. Growing investment in advanced biotechnology research and increasing adoption of genetic engineering approaches are creating sustained opportunities for DNA manufacturers.
Large-scale DNA manufacturing
The growing requirement for large-scale DNA manufacturing is supporting market expansion as biotechnology applications increasingly transition from laboratory research toward clinical development and commercial production. Scalable manufacturing capabilities are essential for producing consistent genetic materials while maintaining quality, sequence accuracy, and production efficiency. The increasing complexity of DNA constructs and rising demand for reliable supply across therapeutic, industrial biotechnology, and research applications are encouraging advancements in large-scale manufacturing processes.
Refine the market drivers further
- strengthen the clinical and technology insights
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| DNA synthesis demand in research | 6% | Short term (≤ 2 yrs) | North America; Europe | Medium | Moderate |
| Gene therapy and synthetic biology | 5% | Medium term (2–5 yrs) | Europe; Asia Pacific | Medium | Moderate |
| Large-scale DNA manufacturing | 3.5% | Long term (5+ yrs) | North America; Asia Pacific | Medium | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The North America DNA manufacturing market dominated the global market, accounting for a 49% share in 2026. The region’s strong position is supported by advanced biotechnology infrastructure, substantial research and development capabilities, and growing demand for high-quality DNA products across pharmaceutical, biotechnology, and life sciences applications. The increasing use of synthetic DNA in genetic engineering, molecular diagnostics, drug discovery, and the development of advanced therapeutics is driving demand for reliable manufacturing capabilities. In addition, the expansion of precision medicine, gene-based research, and biotechnology innovation is increasing the need for scalable DNA synthesis and customized genetic materials. Established research institutions, specialized laboratory infrastructure, and continued investment in life sciences are further supporting market development. The growing importance of genetic technologies in therapeutic development and biomedical research continues to strengthen demand for advanced DNA manufacturing solutions.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific DNA manufacturing market is expected to grow at the fastest pace, driven by expanding biotechnology industries, increasing investments in life sciences research, and rising demand for genetic materials across healthcare and pharmaceutical applications. The growing emphasis on genomics, molecular diagnostics, and personalized medicine is creating opportunities for DNA synthesis and manufacturing services. In addition, expanding research capabilities and increasing adoption of biotechnology tools are supporting the development of regional manufacturing capacity. The need for reliable genetic materials in drug discovery, vaccine development, genetic engineering, and advanced therapeutic research is further encouraging market expansion. As biotechnology ecosystems mature and access to specialized laboratory technologies improves, the region is positioned to strengthen its role in DNA manufacturing and support the growing demand for innovative life sciences applications.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Synthetic Biology Scale-UpThe U.S. DNA manufacturing market is shaped by demand from synthetic biology, biopharma, diagnostics, and research applications. Priorities include scalable production, sequence accuracy, rapid turnaround, and integrated quality controls as organizations move DNA workflows from laboratory development toward larger-scale commercial applications.
Germany 🇩🇪
Biopharma-Grade DNA SupplyGermany’s DNA manufacturing demand is closely linked to biotechnology research, pharmaceutical development, and advanced molecular workflows. Market priorities include high-quality production, regulatory-ready processes, reliable supply, and specialized DNA formats that can support increasingly complex therapeutic and research programs.
Japan 🇯🇵
Precision DNA ProductionJapan’s DNA manufacturing market emphasizes dependable, high-precision supply for pharmaceutical research, diagnostics, biotechnology, and academic applications. Commercial priorities include sequence fidelity, manufacturing consistency, shorter production cycles, and customization capabilities suited to specialized molecular biology workflows.
South Korea 🇰🇷
Biotech Manufacturing IntegrationSouth Korea is integrating DNA manufacturing capabilities into a broader biotechnology and biopharmaceutical ecosystem. Priorities include dependable local or regional supply, scalable synthesis, quality assurance, and support for research and development pipelines requiring increasingly customized DNA constructs.
France 🇫🇷
Research-to-Therapeutics SupplyFrance’s DNA manufacturing market serves academic research, biotechnology, diagnostics, and therapeutic development. Market priorities include reliable custom synthesis, quality documentation, and production capabilities that can support the transition from early molecular research into regulated biopharmaceutical applications.
Italy 🇮🇹
Customized Research SupplyItaly’s DNA manufacturing demand is supported by biotechnology, molecular diagnostics, pharmaceutical research, and academic laboratories. Commercial priorities center on flexible custom synthesis, dependable delivery, sequence quality, and accessible manufacturing services for increasingly specialized research and development requirements.
DNA Manufacturing Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Pharmaceutical and Biotechnology Companies (Largest & Fastest-Growing Segment)
In 2026, the pharmaceutical and biotechnology companies segment accounted for the largest 51.6% share, and is also expected to register the fastest growth. The strong position of this end-use segment is driven by the increasing use of manufactured DNA in drug discovery, genetic research, molecular diagnostics, vaccine development, cell and gene therapies, and other advanced life-science applications. Pharmaceutical and biotechnology organizations require high-quality DNA with precise sequences and reliable production characteristics to support research and development activities as well as increasingly complex therapeutic programs. The expansion of personalized medicine and precision healthcare is creating additional demand for custom DNA sequences tailored to specific research and therapeutic requirements in the DNA manufacturing market. Advances in synthetic biology, genetic engineering, and molecular biology are further increasing the range of applications for manufactured DNA. In addition, growing investment in biotechnology research and the development of next-generation therapeutics are strengthening demand for scalable and reliable DNA manufacturing capabilities, supporting the continued expansion of this end-use segment.
Grade Segment Analysis: GMP Grade (Largest & Fastest-Growing Segment)
The GMP grade segment represents both the largest and fastest-growing grade category share in 2026, supported by the increasing need for DNA products that meet stringent quality, consistency, traceability, and manufacturing standards. GMP-grade DNA is particularly important for applications involving clinical research, therapeutic development, and other processes where product quality and manufacturing controls are critical. The expansion of cell and gene therapy programs is increasing demand for DNA materials produced under rigorous quality-management frameworks, as these applications require dependable inputs throughout development and manufacturing workflows. Growing regulatory expectations and the transition of advanced biological products from research settings toward clinical and commercial applications are further strengthening demand for GMP-compliant manufacturing. Improvements in purification, quality control, analytical characterization, and manufacturing processes are enabling suppliers to deliver DNA products with greater consistency and reliability. As pharmaceutical and biotechnology organizations increasingly require production-ready materials for advanced therapeutic applications, GMP-grade DNA is becoming an increasingly important component of the broader ecosystem in the DNA manufacturing market.
Type Segment Analysis: Synthetic DNA (Largest & Fastest-Growing Segment)
The synthetic DNA segment represents both the largest and fastest-growing type category share in the DNA manufacturing market for 2026, driven by its versatility and expanding role in research, biotechnology, diagnostics, and therapeutic development. Synthetic DNA enables researchers and manufacturers to obtain customized genetic sequences without relying solely on naturally occurring DNA sources, supporting applications such as gene construction, molecular cloning, functional genomics, assay development, and synthetic biology. Advances in DNA synthesis technologies are improving sequence accuracy, production efficiency, customization capabilities, and the ability to manufacture increasingly complex genetic constructs. The growing use of engineered biological systems is creating additional demand for synthetic DNA as researchers design genetic sequences for specialized biological functions and experimental applications. In pharmaceutical and biotechnology development, synthetic DNA is also supporting the creation and optimization of genetic constructs used in advanced therapeutic research. Increasing adoption of synthetic biology, expanding genomic research, and the need for customized genetic materials are therefore supporting sustained growth of the synthetic DNA segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Pharmaceutical and Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations | Pharmaceutical and Biotechnology Companies | Pharmaceutical and Biotechnology Companies |
| Grade | GMP Grade, R&D Grade | GMP Grade | GMP Grade |
| Type | Plasmid DNA, Synthetic DNA, Gene Synthesis, Oligonucleotide Synthesis | Synthetic DNA | Synthetic DNA |
| Application | Cell & Gene Therapy, Vaccines, Oligonucleotide-based Drugs, Others | Cell & Gene Therapy | Cell & Gene Therapy |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Commercial viability in DNA manufacturing is increasingly defined by the operational trade-offs between traditional chemical synthesis and emerging enzymatic methodologies. While chemical approaches remain dominant for short oligonucleotides, enzymatic techniques offer cleaner, longer-sequence assembly, provided platforms can ensure high coupling efficiency, sequence fidelity, and predictable turnaround times without requiring costly post-synthesis correction. Furthermore, high-throughput scale creates value only when paired with rigorous quality control across complex constructs. As centralized foundry services leverage specialized infrastructure to drive down costs for bulk assembly, benchtop synthesis devices gain ground in laboratories prioritizing sequence confidentiality and rapid prototyping, prompting vendors to adapt service models to distinct customer workflows.
Top players in the DNA manufacturing market:
- Thermo Fisher Scientific (USA)
- Twist Bioscience (USA)
- GenScript (China)
- Eurofins Scientific (Luxembourg)
- Integrated DNA Technologies (USA)
- BGI Genomics (China)
- ATUM (USA)
- Evonetix (UK)
- Synbio Technologies (China)
- Codex DNA (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific (USA) | |||||||
| Twist Bioscience (USA) | |||||||
| GenScript (China) | |||||||
| Eurofins Scientific (Luxembourg) | |||||||
| Integrated DNA Technologies (USA) | |||||||
| BGI Genomics (China) | |||||||
| ATUM (USA) | |||||||
| Evonetix (UK) | |||||||
| Synbio Technologies (China) | |||||||
| Codex DNA (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| NunaBio | June 2026 | NunaBio secured £6.5 million in financing to scale its next-generation DNA manufacturing capabilities and expand production operations. This capital infusion accelerates the commercialization of its proprietary DNA synthesis platform to meet rising market demand for advanced manufacturing solutions. |
| 4basebio | May 2026 | 4basebio expanded its operational footprint by establishing a new innovation hub and manufacturing facility in Cambridge, UK. The site is designed to support the growing commercial demand for high-quality synthetic DNA utilized in gene and cell therapies, mRNA vaccines, and genome editing applications. |
| Artis BioSolutions | March 2026 | Artis BioSolutions acquired Spain-based Syngoi Technologies to integrate enzymatic synthetic DNA approaches into its platform. This strategic transaction broadens the company's capabilities in advanced-therapy development and expands its specialized manufacturing footprint. |
| Bionova Scientific | January 2026 | Bionova Scientific partnered with Syenex to serve as the preferred manufacturing provider for advanced delivery platforms. The alliance strengthens Bionova’s operational role in plasmid DNA manufacturing by aligning its production capacity with Syenex delivery technologies. |
| Elegen | October 2025 | Elegen commercialized its Gen II Cell-Free DNA production platform, which integrates microfluidic synthesis with cell-free cloning technology. The platform significantly enhances production speed and quality metrics for synthetic DNA applications across the life sciences sector. |
| Ansa Biotechnologies | October 2025 | Ansa Biotechnologies launched a 50 kb clonal DNA product, establishing a new industry standard for long sequence-perfect synthetic DNA. This commercial release broadened market access to highly accurate, long-sequence DNA products and advanced production capabilities. |
| VGXI, Inc. | May 2025 | VGXI successfully completed a regulatory FDA inspection at its Conroe, Texas, manufacturing facility. This compliance milestone enabled a client to submit a Biologics License Application for plasmid DNA utilized in gene therapies and mRNA vaccines. |
| Eurofins Genomics US | September 2024 | Eurofins Genomics US opened a GMP-certified oligonucleotide manufacturing facility in Louisville, Kentucky, to address rising demand for synthetic DNA and RNA. The facility features dedicated production streams and advanced automation that nearly double the company's manufacturing capacity. |
| Argonaut Manufacturing Services | March 2024 | Argonaut Manufacturing Services secured $45 million in growth financing to fund major facility expansion initiatives. The funding enables the company to increase overall manufacturing capacity and extend its operational footprint as a dedicated life sciences services provider. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
DNA Manufacturing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Production Scale | Small-Scale, Mid-Scale, Large-Scale |
| Manufacturing Platform | In-house Manufacturing, Contract Manufacturing, Hybrid Manufacturing |
| Supply Model | Stock-Based Supply, Made-to-Order Supply, Custom Project-Based Supply |
DNA Manufacturing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Manufacturing Capacity & Supply Resilience |
|
| Customer Make-versus-Buy Decisions |
|
| Biosecurity & Screening Requirements |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How large is the DNA manufacturing market?
What is the anticipated CAGR of the DNA manufacturing industry?
How are gene therapy and synthetic biology expanding demand for DNA manufacturing?
Why is large-scale DNA manufacturing becoming strategically important as biotechnology advances?
Why do pharmaceutical and biotechnology companies dominate the DNA manufacturing market?
How is GMP-grade DNA creating growth opportunities in DNA manufacturing?
What makes North America the leading DNA manufacturing market?
How is Asia Pacific accelerating growth in the DNA manufacturing market?
Which companies are driving growth in the DNA manufacturing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook